HN22C0690

Discovery of Leads as LRRK2 inhibitors for the treat of Crohn's disease

Chung-Ang University, College of Pharmacy

IMMUNOLOGY | **Lead**

Product Type	Small molecule
Indication	Crohn's disease
Target	LRRK2
MoA(Mechanism of Action)	decreasing TNF-alpha production by LRRK2 inhibition
Competitiveness	• High potency having IC50 values in single-digit nanomolar ranges. • High selectivity (only 5 kinases of 468 kinases inhibit more than 60% at 100 nM) • Excellent pharmacokinetic properties: bioavailability : 44% for MKL111, 72% for MKL114, 94% for MKL119 • High safety : weak hERG binding (IC50: 14 and >30 uM for MKL114 and MLK-119, respectively)
Development Stage	Lead
Route of Administration	oral

kddf_bd@kddf.org
KDDF Business Development Team